Sandoz’s chief commercial officer discusses the company’s ambitions plans to have a biosimilar-driven growth engine by 2040.
All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.
The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.
The latest funding would also support an expansion of Basecamp’s pharmaceutical partnerships.
The companies will combine Genialis Supermodel with Inventia’s RASTRUM 3D model platform to study PDAC.
BoomRay focuses on radioligand therapies for precision oncology, spanning candidate discovery and clinical translation activities.
